St. Jude Children's Research Hospital has an outstanding track record of world-class research and innovation, leading to major scientific advances and ground-breaking new inventions in our mission to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Sometimes, discoveries are made that could be beneficial outside of that mission, and can represent significant opportunities for commercial development.
The Office of Technology Licensing patents inventions with commercial potential and offers them to industry for license. Our goal is to encourage the use of our inventions for the development of products that can be used by researchers and clinicians all over the world, thus benefiting the maximum number of patients. You can explore our technology opportunities for inventions and reagents that are currently available to license.
We are always happy to hear from prospective partners – please contact us if you wish to discuss specific technology interests.
Technologies
Below is a list of all technologies currently available at St. Jude Children's Research Hospital.
-
Antibodies for Basic Research
Research Models
Research Reagents
-
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Anti-GD2-BB-zeta Chimeric Receptor for Treating GD2+ Malignancies (SJ-13-0035)
- Antibodies to Tim4 for use as an Immune Enhancer and Cancer Therapeutic (SJ-18-0006)
- Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
- BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
- CD33 CAR (SJ-17-0010)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
- Development and Optimization of a Serotype-Independent Method of Adeno-Associated Virus (AAV) Harvest and Purification (SJ-16-0036)
- DNA Methylation Profile and Biomarkers for identifying functional T-cells (SJ-17-0002)
- DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
- Efficient generation of T-Cell Receptor (TCR) sequences in response to a variety of immune responses (SJ-19-0017)
- Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
- Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
- Generation of Therapeutic T Cell Receptors for Fibrolamellar Cancer (SJ-19-0046)
- HMGA2 in Gene Therapy Vectors (SJ-16-0014)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)
- Improved Method to Produce Proteins to Treat Lysosomal Storage Disorders (SJ-01-0020)
- iNKT Cell Expansion Protocol (SJ-12-0033)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Method for predicting T-cell development stage (and therapy success) (SJ-19-0033)
- Minimized Liver Specific Promoter for Improved Gene Expression in Gene Therapy Vectors (SJ-04-0024)
- New Method for Differentiating T-cells (SJ-18-0019)
- p53 Inhibitory Oligonucloeotides (SJ-09-0015)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
- Regulating p53 Translation and Function (SJ-05-0002)
- RIPK3 Fusion Protein for Treating Cancer and Autoimmunity (SJ-12-0036)
- Safety Test for Gene Therapy Vectors (SJ-15-0027)
-
- A Novel Method for Quantitative Detection of Purines and Their Metabolites (SJ-13-0014)
- AML MRD Markers (SJ-18-0011)
- Assay for Detecting ALK Inhibitor Resistance Mutations (SJ-09-0042)
- Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
- CHANGE-seq: a rapid, high-throughput method to define genome-wide activity of CRISPR-Cas genome editors (SJ-18-0041)
- Detecting TERT Promoter Methylation for Cancer Diagnosis (SJ-16-0015)
- Determining CAR T Cell Effectiveness (SJ-19-0040)
- Genotyping Assay to Predict CYP3A5 Phenotype (SJ-01-0005)
- Medulloblastoma Subtyping Assay (SJ-10-0020)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Markers for Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia (SJ-11-0025)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- XAF-1 Mutations Linked to Cancer Susceptibility (SJ-15-0016)
-
- BET Bromodomain Inhibitors (SJ-16-0032)
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- CXorf67-PRC2 Interaction and Ependymoma (SJ-17-0030)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- Improved Human Carboxylesterase for Therapy with CPT-11 (SJ-06-0006)
- Method for Improving Learning and Treating Neurological Diseases (SJ-15-0009)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)
- Novel Carboxylesterase Inhibitors (SJ-02-0030)
- SARM for Kennedy's Disease (SJ-18-0012)
- SPA70 is a potent antagonist of human pregnane X receptor (PXR Antagonists) (SJ-16-0011)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
- Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
- Transcription Factors for Cochlear Hearing Loss Therapy (SJ-17-0016)
- Treating Cochlear Hearing loss with p27Kip1/Atoh1 Combinations (SJ-13-0019)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
- Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)
-
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Alternate mTOR Pathway (SJ-09-0021)
- ARF and HDM2 interaction domains (SJ-01-0016)
- Assay for ATM Kinase Modulation (SJ-02-0008)
- BMP Compounds for treating diseases caused by defective or diminished BMP signaling (Medulloblastoma) - (SJ-15-0008)
- Caspase 1 inhibition to overcome glucocorticoid resistance (SJ-13-0039)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- Cells That Lack p19Ink4d and p27Kip1 Activity/p19Ink4d and p27Kip1 Null Mice (SJ-98-0023)
- Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
- DCN1 Inhibitors (SJ-16-0002)
- Defects in LC3-associated phagocytosis (LAP) associated with Lupus (SJ-16-0025)
- Discovery of a fluorescent vinblastine analog with high affinity to the human pregnane X receptor (hPXR) Ligand (SJ-13-0009)
- Discovery of a novel inhibitor of constitutive androstane receptor (CAR) that does not activate pregnane X receptor (PXR) (SJ-14-0039)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- Hematopoietic progenitor cell lines with myeloid and lymphoid potential (SJ-11-0003)
- Identification of Toll-like receptor signaling inhibitors (SJ-18-0008)
- Improving HSC Engraftment by Inhibiting GASP Genes (SJ-16-0029)
- Interaction of Reelin With Very Low Density Lipoprotein (VLDL) Receptor (SJ-98-0045)
- LANDO Pathway Disruption for Alzheimer's Disease (SJ-19-0020)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- Modulating Non-Canonical Autophagy (LAP) in Myeloid Cells to Suppress Tumors (SJ-17-0019)
- Ozz, A Protein That Regulates Development and Function of Muscle Cells (SJ-99-0010)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
- Regulating p53 Translation and Function (SJ-05-0002)
- Respiratory Cell Isolation and Propagation for Pathogen Study (SJ-18-0028)
- SCCRO Peptide Inhibitor (SJ-11-0014)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
-
- General Architecture for Defining and Collecting Data (SJ-03-0005)
- Multi-slice Myelin Water Imaging (SJ-12-0009)
- Phase Cycled Magnetic Resonance Spectroscopic Imaging (SJ-15-0032)
- Primary Template-Directed Amplification (PTA) (SJ-18-0003)
- ProteinPaint: Web Application for Visualizing Genomic Data (SJ-15-0021)
- Statistical Framework for Clinical DNAemia Assays (SJ-18-0039)
- System Design and Method for Verifying 3D Dosimetric Imaging (SJ-15-0022)
-
- Attenuated Streptococcus Pneumoniae Strain and Vaccine for Protection Against Pneumococcal Disease (SJ-11-0001)
- Avian Influenza Vaccine (SJ-06-0013)
- Group B Streptococcus (GBS) Extracellular Matrix Adhesion Proteins (SJ-00-0030)
- Improved System for Generating Human Influenza Vaccine in Cell Tissue Culture (SJ-02-0016)
- Methods and Composition for Diagnosing and Preventing a Group B Streptococcal Infection (SJ-02-0032)
- Modified Influenza Virus for Monitoring and Improving Vaccine Efficiency (SJ-04-0033)
- Modified Sendai Virus Vaccine and Imaging Vector (SJ-11-0018)
- Reverse Genetics System for Generating RNA Viruses and Vaccines (SJ-00-0006)
- Screen to Identify Pneumococcal Proteins that Inhibit Transmission Rather than Invasive Disease (SJ-18-0045)
- Screen to Identify Pneumococcal Proteins that Inhibit Transmission Rather than Invasive Disease (SJ-18-0045)
- Synthetic Vaccine and Immunogenic Fusion Proteins for Pneumococcal Infections, and uses (SJ-05-0036, SJ-10-0028, SJ-13-0032)
- Universal Influenza Vaccine (SJ-05-0040)